PITTSBORO, NC--(MARKET WIRE)--Jul 13, 2007 -- Biolex Therapeutics announced today that Company researchers have presented results at the XXIst Congress of The International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland demonstrating that full-length recombinant plasmin (BLX-155) produced with the Company’s proprietary LEX System(SM) is indistinguishable from human plasma-derived plasmin in characterization and activity. Full-length, active plasmin has been proposed as a potential thrombolytic agent for several decades, and the LEX System is the first recombinant expression system reported to produce commercially viable levels of full-length plasmin. This achievement provides Biolex the opportunity to pursue development and commercialization of a therapeutic protein with a recognized mechanism of action for which development historically has been blocked by production challenges. The Company also announced that clinical studies of BLX-155 are planned to commence in the first half of 2008.
